Products for Research Use Only

A-1331852

CAT: 0013-GTR19163240-01Size: 200 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0013-GTR19163240-01Size:200 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
A-1331852 is a potent and selective BCL-XL inhibitor (Ki<10 pM) ; shows much weaker affinity for BCL-2 (Ki=6 nM), BCL-W (Ki=4 nM), and MCL-1 (Ki=142 nM) ; selectively disrupts BCL-XL–BIM complexes and induces the hallmarks of apoptosis in BCL-XL–dependent Molt-4 cells (Molt-4 viability IC50=6 nM) ; demonstrates antitumor efficacy in the Molt-4 xenograft model; orally active. (In Vitro) :A-1331852 selectively disrupts BCL-XL–BIM complexes and induces the hallmarks of apoptosis in BCL-XL–dependent Molt-4 cells with IC50s in the low nanomolar range but does not affect MEF cells lacking BAK or BAX. In CellTiter-Glo cell viability assay, A-1331852 inhibits NCI-H847, NCI-H1417, SET-2, HEL, OCI-M2 with EC50 values of 3, 7, 80, 120 and 100 nM. (In Vivo) :A-1331852 demonstrates antitumor efficacy in the Molt-4 xenograft model, inducing tumor regressions as a single agent. Additionally, A-1331852 combines with venetoclax to recapitulate the efficacy of navitoclax in the NCI-H1963.FP5 xenograft model of SCLC. A-1331852 significantly inhibits tumor growth in seven subcutaneous xenograft models of solid tumors, including breast cancer, NSCLC, and ovarian cancer.
CAS Number
1430844-80-6
Product Name Alternative
A1331852 | A 1331852
Purity
>98% (HPLC)
Solubility
DMSO: ≥ 12 mg/mL
Smiles
CC1=C (C=NN1CC23CC4CC (C2) CC (C4) C3) C5=C (N=C (C=C5) N6CCC7=CC=CC (=C7C6) C (=O) NC8=NC9=CC=CC=C9S8) C (=O) O
Molecular Formula
C38H38N6O3S
Molecular Weight
658.8117
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
2-Pyridinecarboxylic acid, 6-[8-[ (2-benzothiazolylamino) carbonyl]-3,4-dihydro-2 (1H) -isoquinolinyl]-3-[5-methyl-1- (tricyclo[3.3.1.13,7]dec-1-ylmethyl) -1H-pyrazol-4-yl]-

Alternative Products